Patients with type 2 diabetes mellitus have a twofold increased risk of cardiovascular mortality compared with non-diabetic individuals. There is a growing awareness that glycemic efficacy of anti-diabetic drugs does not necessarily translate to cardiovascular safety. Over the past few years, there has been a number of trials evaluating the cardiovascular effects of anti-diabetic drugs. In this...

UNLABELLED Considering increased use of cardiovascular drugs and limitations in pre-marketing trials for drug safety evaluation, post marketing evaluation of adverse drug reactions (ADRs) induced by this class of medicinal products seems necessary. OBJECTIVES To determine the rate and seriousness of adverse reactions induced by cardiovascular drugs in outpatients. To compare sex and different...

Cardiovascular disease is the leading cause of mortality and morbidity among diabetic patients. There by reducing cardiovascular risk is a major focus of diabetic management. International Diabetes Federation (IDF) in 2014 has projected that 592 million population will be affected by diabetes by the year 2035 from the present status of 387 million out of which 90% will have type 2 diabetes. The...

background: benzodiazepine (bzd) toxicity alone or with other drugs is common in poisoning emergency departments of iran. the aim of this study was to evaluate the cardiovascular findings in patients with benzodiazepine poisoning upon admission to the emergency department. methods: in a prospective study which was followed by retrospective analysis, 267 patients poisoned with bzd were evaluated...